AU2019406803B2 - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
AU2019406803B2
AU2019406803B2 AU2019406803A AU2019406803A AU2019406803B2 AU 2019406803 B2 AU2019406803 B2 AU 2019406803B2 AU 2019406803 A AU2019406803 A AU 2019406803A AU 2019406803 A AU2019406803 A AU 2019406803A AU 2019406803 B2 AU2019406803 B2 AU 2019406803B2
Authority
AU
Australia
Prior art keywords
disorders
compound
compound according
disorder
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019406803A
Other languages
English (en)
Other versions
AU2019406803A1 (en
Inventor
Robert Davis
Peng Li
Yupu QIAO
Kimberly Vanover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2019406803A1 publication Critical patent/AU2019406803A1/en
Application granted granted Critical
Publication of AU2019406803B2 publication Critical patent/AU2019406803B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU2019406803A 2018-12-17 2019-12-17 Organic compounds Active AU2019406803B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
US62/780,703 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (2)

Publication Number Publication Date
AU2019406803A1 AU2019406803A1 (en) 2021-07-08
AU2019406803B2 true AU2019406803B2 (en) 2025-04-24

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019406803A Active AU2019406803B2 (en) 2018-12-17 2019-12-17 Organic compounds

Country Status (11)

Country Link
US (1) US12325726B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897656A4 (cg-RX-API-DMAC7.html)
JP (1) JP7645797B2 (cg-RX-API-DMAC7.html)
KR (1) KR102931436B1 (cg-RX-API-DMAC7.html)
CN (1) CN113226326B (cg-RX-API-DMAC7.html)
AU (1) AU2019406803B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011765A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121636A1 (cg-RX-API-DMAC7.html)
IL (1) IL283960B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021007142A (cg-RX-API-DMAC7.html)
WO (1) WO2020131918A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
US20230416300A1 (en) * 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240589A1 (en) * 2014-10-16 2017-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
DK2168585T3 (da) * 2005-06-09 2012-02-27 Euro Celtique Sa Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US20170233433A1 (en) * 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US12325726B2 (en) 2018-12-17 2025-06-10 Intra-Cellular Therapies, Inc. Organic compounds
US20230416300A1 (en) 2020-08-20 2023-12-28 Intra-Cellular Therapies, Inc. Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240589A1 (en) * 2014-10-16 2017-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Also Published As

Publication number Publication date
IL283960B2 (en) 2025-09-01
AU2019406803A1 (en) 2021-07-08
US20220073558A1 (en) 2022-03-10
BR112021011765A2 (pt) 2021-08-31
IL283960A (en) 2021-07-29
EP3897656A4 (en) 2022-09-21
IL283960B1 (en) 2025-05-01
JP2022513933A (ja) 2022-02-09
CN113226326A (zh) 2021-08-06
KR20210105934A (ko) 2021-08-27
MX2021007142A (es) 2021-08-11
US12325726B2 (en) 2025-06-10
CA3121636A1 (en) 2020-06-25
KR102931436B1 (ko) 2026-02-25
WO2020131918A1 (en) 2020-06-25
CN113226326B (zh) 2024-09-20
EP3897656A1 (en) 2021-10-27
JP7645797B2 (ja) 2025-03-14

Similar Documents

Publication Publication Date Title
US12325726B2 (en) Organic compounds
WO2022040545A1 (en) Organic compounds
JP7387590B2 (ja) ラパマイシン誘導体
EP3612517B1 (en) Bicyclic compounds and their use in the treatment of cancer
AU2017238858A1 (en) Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
CA2372342A1 (en) 3.alpha.-hydroxy-3.beta. methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
US10519193B2 (en) Steroidal compound, composition containing the same and use thereof
CN114206899A (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
CA3182354A1 (en) Methyl 2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1h-cyclopenta[b]pyridine-3-carboxylates and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates as cav1.2 activators
JP2021500309A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
JP7750582B2 (ja) 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途
RU2809023C2 (ru) Органические соединения
HK40058207A (en) Organic compounds
EP4165048B1 (en) Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators
EP3778589B1 (en) 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
US20250163062A1 (en) Wnt pathway inhibitor compounds
HK40058207B (en) Organic compounds
JP2024545200A (ja) CaV1.2活性剤としてのピリジン-3-カルボキシレート化合物
HK40082497A (en) Fused imidazole derivatives, preparation method and medical use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)